�Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of oral pitch systems, proclaimed successful results from the clinical run of its oral insulin capsule, ORMD 0801. The trial demonstrated that the product had a salutary safety visibility and well tolerated and effective in lowering blood glucose levels in patients with type 2 diabetes.
The study was conducted at Hadassah University Medical Center in Jerusalem and was a continuation of the successful Phase 1B trials that Oramed completed earlier this year.
This trial was the low gear to display patients with type 2 diabetes to ORMD 0801 and its primary goals were to assess the safety, tolerability and pharmcodynamic effects in these patients.
ORMD 0801 was good tolerated by all patients and had a proficient safety profile; no good adverse events were encountered throughout the study. In 6 of the 9 subjects analyzed, statistically important reductions in glucose as well as C-peptide were observed.
"We are pleased with the results from the Phase 2A trial as they show that ORMD 0801 was effective and there were no safety issues," said Oramed's Chief Scientist, Dr. Miriam Kidron. "We look fore to our next phase of testing and taking the next steps towards making an oral insulin capsule a reality for millions of diabetics about the world."
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology initiate in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is quest to revolutionise the treatment of diabetes through its patented flagship product, an orally ingestible insulin space capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
For more information, please visit hTTP://www.oramed.com
Forward-looking statements
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which whitethorn cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, carrying into action or achievements expressed or implied by such fore looking statements, including the risks and uncertainties related to to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional financial support required to conduct its research, exploitation and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause real results, performance or achievements of the company to differ materially from those expressed or implied in such fore looking statements. The company undertakes no obligation to update or revise any forward-looking statements.
Oramed Pharmaceuticals
More info
Wednesday 13 August 2008
Wednesday 6 August 2008
Novel Study Finds Proton Channels Inhibit The Release Of Histamine During Allergic Reactions
�Inhibiting the proton currents in basophils, a rare type of white blood cell, hind end stop the release of histamine and could provide a new target for allergy and asthma drugs according to a new study by researchers at Rush University Medical Center in Chicago and the Johns Hopkins Asthma and Allergy Center in Baltimore. The research is published in the August fifth issue the Proceedings of the National Academy of Sciences.
When allergens enter the body, they can be recognized by IgE antibodies bound to basophils, causation these white blood cells to acquittance the incitive chemical histamine. Histamine causes several allergic symptoms, including airway constriction in the lungs, stern itching, urtication and swelling, and is a major cause of asthma.
Basophils ar among various cell types that state unique ion channels called voltage-gated proton channels. Ion channels open and close providing william Henry Gates for ions, or charged electrical particles, to enter or leave cells. This in turn controls the function of the cadre. Voltage-gated proton channels only allow protons to will cells and seem to be intentional to speedily and efficiently force blistering from cells.
Previously the function of the proton channels in basophils was unknown. Researchers at Rush have determined these channels are important in the process of histamine release.
"Our research shows that proton channels in basophils respond vigorously to agents that fire histamine release," said Thomas DeCoursey, PhD, professor of molecular biophysics and physiology at Rush. "We also determined that histamine was inhibited by zinc at concentrations that inhibit proton currents, ordered with the idea that proton groove activity is linked to basophil activation."
According to DeCoursey, this research points to a new target for drug developers. Prevent the channel from working and that would stop the release of histamine. Currently, the most potent inhibitor is zn, but zinc is toxic in high concentrations and the body regulates atomic number 30 levels identical closely. The goal is to develop a more selective inhibitor of the proton channel that would bind to it and prevent its activity without doing harm.
"It is exciting to discover a novel function for proton channels," said DeCoursey. "We believe this research could lead to young approaches to reduce the potentially lethal consequences of asthma and allergic reactions."
Rush University Medical Center
1700 W Van Buren, Ste. 250
Chicago, IL 60012
United States
http://www.rush.edu
More info
When allergens enter the body, they can be recognized by IgE antibodies bound to basophils, causation these white blood cells to acquittance the incitive chemical histamine. Histamine causes several allergic symptoms, including airway constriction in the lungs, stern itching, urtication and swelling, and is a major cause of asthma.
Basophils ar among various cell types that state unique ion channels called voltage-gated proton channels. Ion channels open and close providing william Henry Gates for ions, or charged electrical particles, to enter or leave cells. This in turn controls the function of the cadre. Voltage-gated proton channels only allow protons to will cells and seem to be intentional to speedily and efficiently force blistering from cells.
Previously the function of the proton channels in basophils was unknown. Researchers at Rush have determined these channels are important in the process of histamine release.
"Our research shows that proton channels in basophils respond vigorously to agents that fire histamine release," said Thomas DeCoursey, PhD, professor of molecular biophysics and physiology at Rush. "We also determined that histamine was inhibited by zinc at concentrations that inhibit proton currents, ordered with the idea that proton groove activity is linked to basophil activation."
According to DeCoursey, this research points to a new target for drug developers. Prevent the channel from working and that would stop the release of histamine. Currently, the most potent inhibitor is zn, but zinc is toxic in high concentrations and the body regulates atomic number 30 levels identical closely. The goal is to develop a more selective inhibitor of the proton channel that would bind to it and prevent its activity without doing harm.
"It is exciting to discover a novel function for proton channels," said DeCoursey. "We believe this research could lead to young approaches to reduce the potentially lethal consequences of asthma and allergic reactions."
Rush University Medical Center
1700 W Van Buren, Ste. 250
Chicago, IL 60012
United States
http://www.rush.edu
More info
Subscribe to:
Posts (Atom)